Friday, May 15, 2026
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Overview. MariMed reported another solid quarter, even with the adverse market dynamics that persist across the cannabis industry. Management’s focus on its Expand the Brand strategy is paying dividends, with MariMed products maintaining market-leading positions across all of its core markets. The Company grew revenue y-o-y, generated positive adjusted EBITDA, and positive cash flow from operations.
1Q26 Results. Revenue of $39.5 million rose 4.2% y-o-y and exceeded our $38.3 million estimate, driven by expanded wholesale distribution and retail growth. Adjusted gross margin came in at 40.1% versus 41.2% last year. Adjusted EBITDA totaled $3.6 million, up from $2.5 million in 1Q25. MariMed reported an adjusted net loss of $3.2 million, compared to a net loss of $3.9 million in 1Q25.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
